Tris wins FDA OK for Karbinal in allergic rhinitis
This article was originally published in Scrip
Executive Summary
Tris Pharma won the US FDA's approval to market Karbinal ER (carbinoxamine maleate) as the first sustained-release histamine receptor blocking agent indicated to treat seasonal and perennial allergic rhinitis in children 2 years or up.